南财智讯1月29日电，诺唯赞发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为-2000 万元至-1000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为-8500万元 至-7000万元。2025年度，公司预计出现亏损，主要原因如下：报告期内，预计实现的营业收入与上年 同期基本持平，主要系公司生物制品类产品增值税率由3%调整至13%，对整体营收与盈利产生不利影 响；报告期内，公司积极应对外部环境变化影响，加强技术与产品研发，优化降本增效举措，提升经营 效率，不断巩固公司科技创新实力与市场竞争力。同时，公司保持市场投入强度，积极拓展创新业务与 海外市场，销售费用同比有所增长，对当期经营结果有一定不利影响；报告期内，公司基于实际情况与 审慎性原则，计提了部分信用减值损失和资产减值损失，亦对当期经营结果产生一定不利影响。 ...

资料显示，南京诺唯赞生物科技股份有限公司位于江苏省南京经济技术开发区科创路红枫科技园D2 栋，成立日期2012年3月16日，上市日期2021年11月15日，公司主营业务涉及围绕酶、抗原、抗体等功 能性蛋白及高分子有机材料进行技术研发和产品开发的生物科技企业,依托于自主建立的关键共性技术 平台,先后进入了生物试剂、体外诊断业务领域,并正在进行抗体药物的研发。主营业务收入构成为：生 物试剂81.86%，诊断试剂9.99%，耗材等材料3.15%，仪器设备2.96%，技术服务1.85%，其他0.18%。 截至9月30日，诺唯赞股东户数9447.00，较上期增加9.90%；人均流通股42101股，较上期减少9.01%。 2025年1月-9月，诺唯赞实现营业收入9.52亿元，同比减少3.40%；归母净利润661.52万元，同比减少 63.57%。 1月22日，诺唯赞涨0.70%，成交额3500.56万元。两融数据显示，当日诺唯赞获融资买入额165.45万 元，融资偿还336.77万元，融资净买入-171.32万元。截至1月22日，诺唯赞融资融券余额合计1.23亿 元。 融资方面，诺唯赞当日融资买入165.45万元。当前融 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2026-001 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 6 6 月 | 年 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 12.77万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.03% | | | | | | | ...

诺唯赞公告称，公司于2025年6月19日通过回购股份议案，预计用500万元 - 1000万元自有资金，以不超 30元/股的价格回购股份，用于员工持股计划或股权激励，回购期限至2026年6月18日。截至2025年12月 31日，公司累计回购12.77万股，占总股本的0.03%，累计已回购金额299.97万元，实际回购价格区间为 23.06元/股 - 24.36元/股。 ...

Core Insights - The GLP-1 sector is experiencing significant growth potential, and the company is leveraging its upstream raw material supply advantages to explore the GLP-1 peptide raw material market [2] - The company has successfully provided hundreds of kilograms of supply to multiple domestic clients during the 2024 reporting period, complying with GMP standards [2] - The company is focused on enhancing its product and service advantages across the GLP-1 fermentation recombinant method value chain, addressing client needs for product quality, cost, and capacity [2] Business Operations - The company has engaged in compliance submissions and audits with several clients, ensuring adherence to regulatory standards [2] - Ongoing efforts include advancing the DMF filing for core enzyme raw materials and intermediates to support clients' compliance submissions [2] - The business faces uncertainties in future performance due to market competition, supply-demand changes, technological iterations, and geopolitical factors [2]

Group 1 - The core viewpoint of the article is that the company, 诺唯赞, has confirmed it is not planning any changes to its controlling rights as of now [1] Group 2 - The company responded to investor inquiries on its interactive platform regarding the status of its controlling rights [1]

Core Viewpoint - The company, Novozymes, is focused on providing core raw materials and reagents necessary for the production of semaglutide through synthetic biology fermentation methods, catering to various downstream clients [1] Group 1: Product Offerings - The GLP-1 product line includes high specificity and high-capacity raw enzymes and various specifications of intermediate peptides [1] - The company has developed comprehensive quality control testing kits to ensure product reliability [1] Group 2: Client Engagement - Novozymes has successfully supplied hundreds of kilograms of materials to multiple domestic clients [1] - The company offers customized process optimization solutions to enhance production efficiency for its clients [1] Group 3: Production Scope - Currently, the company does not engage in the production of related weight-loss medications [1]

Core Viewpoint - The company Novozymes (688105.SH) has announced its GLP-1 product line and solutions, which primarily provide essential raw materials and reagents needed for the biological fermentation production of Semaglutide for downstream customers [1] Group 1 - The product offerings include highly specific and high-capacity raw enzymes and various specifications of intermediate peptides, accompanied by comprehensive quality control testing kits [1] - The company has successfully supplied hundreds of kilograms to multiple domestic clients [1] - To meet diverse customer needs, the company offers customized process optimization solutions to help clients improve production efficiency [1] Group 2 - Currently, the company does not engage in the production of related weight-loss drugs [1]

Core Viewpoint - The biopharmaceutical sector experienced a slight decline of 0.34% on December 30, with Wanze Co., Ltd. leading the losses. The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1]. Group 1: Market Performance - The biopharmaceutical sector's performance showed mixed results, with individual stocks experiencing varying degrees of gains and losses. Notably, Aidi Pharmaceutical saw a rise of 4.10% to close at 15.98, while Wanze Co., Ltd. fell by 6.76% to 21.94 [1][2]. - The trading volume for Aidi Pharmaceutical was 93,900 shares, with a transaction value of 150 million yuan, indicating strong investor interest [1]. Group 2: Capital Flow - The biopharmaceutical sector faced a net outflow of 330 million yuan from institutional investors, while retail investors contributed a net inflow of 349 million yuan, suggesting a shift in investor sentiment [2]. - The data indicates that while institutional investors withdrew funds, retail investors were more active in purchasing shares within the sector [2][3]. Group 3: Individual Stock Analysis - Ganne Pharmaceutical experienced a net outflow of 34.73 million yuan from institutional investors, while retail investors showed a net inflow of 129.36 million yuan, reflecting a divergence in investment strategies [3]. - Other notable stocks included Huashan Biological, which had a net inflow of 430.99 million yuan from institutional investors, indicating positive sentiment towards its performance [3].

Group 1 - The biopharmaceutical sector increased by 0.18% on December 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Key stocks in the biopharmaceutical sector showed various performance, with Jindike (688670) rising by 4.66% to a closing price of 22.45 [1] Group 2 - The biopharmaceutical sector experienced a net outflow of 307 million yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2] - Notable declines included Te Bao Biological (688278), which fell by 3.14% to a closing price of 80.90 [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Wan Ze Co. (000534) achieving a turnover of 488 million yuan [1][2] Group 3 - Jindike (688670) had a net inflow of 25.23 million yuan from institutional investors, while retail investors had a net outflow of 23.95 million yuan [3] - Other stocks like Zhi Xiang Jin Tai (688443) and Shen Zhou Cell (688520) also showed mixed net inflows and outflows from different investor categories [3] - The overall trend indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors increased their positions [2][3]